Scientists find a new way to protect against lethal fungal infections
Scientists at the Institute of Molecular Biotechnology (IMBA) and the Max F. Perutz Laboratories (MFPL) in Vienna have discovered a new way to turn the immune system’s weapons against fungal invaders. This knowledge could lead to the development of new and improved anti-fungal treatments.
An international team led by researchers at the Austrian Institute of Molecular Biotechnology (IMBA) in Vienna and the University of Maryland School of Medicine in Baltimore discovered that genetically determined breast cancer can be largely prevented by blocking a bone gene. An already approved drug could be quickly available and would then be the first breast cancer prevention drug.
Researchers at IMBA – Institute of Molecular Biotechnology of the Austrian Academy of Sciences have discovered that an enzyme called HACE1 is the key regulator of the death receptor TNFR1. The TNF receptor 1 is located on the cell membrane and decides whether a cell will live or die.
Three ERC-Grants for Research Groups at the Vienna Biocenter
Jürgen Knoblich of the Institute of Molecular Biotechnology (IMBA) as well as Jan-Michael Peters and Tim Clausen of the Research Institute of Molecular Pathology (IMP) each receive an Advanced Grant by the European Research Council ERC. That means a success rate of 100 percent for the two institutes. Researchers at the Vienna Biocenter have received a total of 36 ERC-Grants so far.
The Vienna Biocenter in the third district of Vienna has established itself as the premier location for life sciences in Central Europe and is a world-leading international bio-medical research center.